You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 23, June 21, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (8)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Oncology
 •Breast Cancer
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Statins and the Risk of Cancer

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We believe that the conclusion from the meta-analysis by Dr Dale and colleagues1 that statin therapy has no effect on prostate cancer should be viewed with skepticism. Although the study considered randomized placebo-controlled trials exclusively, these trials were not designed to assess cancer incidence or mortality. Only 3 of 26 trials reported specific prostate cancer incidence data (305 cases), and only 1 of 26 trials reported prostate cancer–specific mortality, with only 2 deaths. The duration of 17 of 26 trials in the meta-analysis was 4 years or less. For prostate cancer and other cancers with a prolonged clinical course, effects on incidence or cancer-specific survival would not likely arise during the study period; stage-specific indicators would be needed to observe any treatment effects.2

In addition, no conclusion can be drawn about the benefits arising from reductions in cholesterol synthesis or circulating cholesterol levels, which have emerged in . . . [Full Text of this Article]

Michael R. Freeman, PhD
michael.freeman@childrens.harvard.edu
Urological Diseases Research Center

Keith R. Solomon, PhD
Department of Orthopaedic Surgery
Children's Hospital Boston
Boston, Mass

Mark Moyad, MD
Department of Urology
University of Michigan Medical Center
Ann Arbor



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Statins and Cancer Risk: A Meta-analysis
, , , , and
JAMA. ;295():74-80.
FULL TEXT  

Statins and the Risk of Cancer
, , and
JAMA. ;295():2720-2720.
FULL TEXT  

Statins and the Risk of Cancer
, , , and
JAMA. ;295():2721-2721.
FULL TEXT  

Statins and the Risk of Cancer--Reply
and
JAMA. ;295():2721-2722.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial
Dore et al.
ANN INTERN MED 2009;150:9-18.
ABSTRACT | FULL TEXT  

Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study
Agalliu et al.
Am J Epidemiol 2008;168:250-260.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.